PARIS, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) announced today that they have entered a strategic partnership that ...
NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will ...
Genfit, a Phase 3 French biotech developing therapies for NASH, raised $135 million by offering 6.65 million ADSs at $20.32 per ADS. It had previously filed to raise $132 million by offering 5.0 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results